Recent treatment advances and practical management of hepatitis D virus

Kathryn Olsen, Sara Mahgoub, Sarah Al-Shakhshir, Akram Algieder, Sowsan Atabani, Ayman Bannaga*, Ahmed M. Elsharkawy

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)

Abstract

Hepatitis D virus (HDV), also referred to as hepatitis delta virus, is the smallest virus capable of causing human disease. It is unable to replicate on its own and can only propagate in the presence of hepatitis B virus (HBV). Infection with both HBV and HDV frequently results in more severe disease than HBV alone, with higher instances of cirrhosis, liver failure and hepatocellular carcinoma (HCC). Thus, there is a need for effective treatment for HDV; however, currently approved treatment options are very limited both in terms of their efficacy and availability. This makes the management of HDV a challenge for physicians. In this review, we look at the background, diagnosis and treatment of HDV, informed by our hospital data, to set out the optimal management of HDV; we also explore novel treatment options for this disease.

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalClinical Medicine, Journal of the Royal College of Physicians of London
Volume23
Issue number4
DOIs
Publication statusPublished - Jul 2023
Externally publishedYes

Bibliographical note

Publisher Copyright:
© Royal College of Physicians 2023.

Keywords

  • Hepatitis D virus
  • bulevirtide
  • lonafarnib
  • nucleic acid polymer REP 2139
  • pegylated interferon

Fingerprint

Dive into the research topics of 'Recent treatment advances and practical management of hepatitis D virus'. Together they form a unique fingerprint.

Cite this